0.000USD0.000åå ŽååŒÂ 08/03, 09:30 (ET)
509.43MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
5.550å§å€
5.605é«å€
2.08Måºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
2.10%売買å転ç
5.630忥çµå€
5.110å®å€
7.28M売買代é
63.69æ ªäŸ¡åçç
4.46PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-64.39%ç·è³ç£å©çç
18.90052é±é«å€
0.78åºæ¥é«æ¯ç%
8.00MçŽå©ç
99.29Mæ ªåŒæ°
-2.00231æ ªåœããå©çïŒEPSïŒ
0.94ããŒã¿å€
-136.40%èªå·±è³æ¬å©çç
6.66052é±å®å€
8.79%æ¯ãå¹
72.29%ç²å©çç
509.43MæäŸ¡ç·é¡
-8.01ãªã¹ã¯ãªã¿ãŒã³
4.05%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
ARS Pharmaceuticals Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå®å®ã§ããæé·ã®å¯èœæ§ã¯é¡èã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž24äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ãã匷ãè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯29.75ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§éåžžã«äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
ARS Pharmaceuticals Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
ARS Pharmaceuticals Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
匷åè²·ã
çŸåšã®è©äŸ¡
ARS Pharmaceuticals Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
çŸåšã®è©äŸ¡
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
ARS Pharmaceuticals Inc
SPRY
4
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
ææšî
ææš
売ã(5)
äžç«(0)
è²·ã(0)
ç§»åå¹³å
売ã(6)
äžç«(0)
è²·ã(0)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ARS Pharmaceuticals Incã®äŒæ¥æ
å ±î
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
äŒæ¥ã³ãŒãSPRY
äŒæ¥åARS Pharmaceuticals Inc
æé«çµå¶è²¬ä»»è
ãCEOãLowenthal (Richard E)
ãŠã§ããµã€ãhttps://ars-pharma.com/
æ ªäž»çµ±èšî
ãããã質å
ARS Pharmaceuticals IncïŒSPRYïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îARS Pharmaceuticals IncïŒSPRYïŒã®çŸåšã®æ ªäŸ¡ã¯5.13ã§ãã
ARS Pharmaceuticals Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îARS Pharmaceuticals Incã®ãã£ãã«ãŒã·ã³ãã«ã¯SPRYã§ãã
ARS Pharmaceuticals Incã®52é±é«å€ã¯ãããã§ããïŒ
îARS Pharmaceuticals Incã®52é±é«å€ã¯18.90ã§ãã
ARS Pharmaceuticals Incã®52é±å®å€ã¯ãããã§ããïŒ
îARS Pharmaceuticals Incã®52é±å®å€ã¯6.66ã§ãã
ARS Pharmaceuticals Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îARS Pharmaceuticals Incã®æäŸ¡ç·é¡ã¯509.43Mã§ãã
ARS Pharmaceuticals Inc (SPRY) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãARS Pharmaceuticals IncïŒSPRYïŒã®ç·åè©äŸ¡ã¯STRONG BUYã§ãç®æšæ ªäŸ¡ã¯29.75ã§ãã
ARS Pharmaceuticals Inc (SPRY) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îARS Pharmaceuticals IncïŒSPRYïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-1.74ã§ãã